Drug Profile
Research programme: anti-infectives - Transave
Alternative Names: Anti-infectives research programme - Transave; SLIT™ TR04; TR 04Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Transave
- Developer Insmed
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Anthrax
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Anthrax in USA (Inhalation, Controlled release)
- 02 Dec 2010 Transave has been acquired and merged into Insmed
- 22 Jun 2005 This programme is still in active development - (BIO-2005)